-+ 0.00%
-+ 0.00%
-+ 0.00%

Allogene Therapeutics hosts CAR T access panel at ASH annual meeting

PUBT·11/20/2026 13:03:17
Listen to the news
Allogene Therapeutics hosts CAR T access panel at ASH annual meeting
  • Allogene Therapeutics will host a CAR T access event Dec. 13, 2026, at the ASH annual meeting in New Orleans.
  • The program will feature research surveying 152 hematologists and oncologists, with a physician panel examining treatment barriers and community adoption.
  • A Natera-hosted showcase on Dec. 12, 2026, will feature ALPHA3, the pivotal trial evaluating cema-cel as MRD-guided first-line consolidation in large B-cell lymphoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200800PRIMZONEFULLFEED9881873) on November 20, 2026, and is solely responsible for the information contained therein.